T5	Effect 24 60	carboplatin (CBDCA) hypersensitivity
T6	Treatment 67 159;212 248	weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy multiple platinum-based chemotherapy
T7	Subject 163 201	patients with recurrent ovarian cancer
T10	Drug 83 93	paclitaxel
T11	Dosage 74 82;95 103	low-dose 60 mg/m2
T12	Drug 105 110	CBDCA
T14	Freq 67 73	weekly
T15	Treat-Disorder 177 201	recurrent ovarian cancer
T17	Drug 24 35	carboplatin
T13	Population 10 14	five
T18	Drug 221 229	platinum
T19	Route 236 248	chemotherapy
T8	Adverse_event 61 66	after
T16	Combination 104 105	/
E1	Adverse_event:T8 
E2	Combination:T16 arg:T10 arg2:T12 arg3:T18